Oaktree Capital, an American global asset management firm, and Qatar Investment Authority, a sovereign wealth fund, agreed to invest $260m in BioXcel Therapeutics, a clinical-stage biopharmaceutical company. “We are delighted to partner with BioXcel Therapeutics during this upcoming period of anticipated growth, highlighted by the recent approval and anticipated commercial launch of IGALMI as an acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The Company has an exciting, AI-driven approach to drug discovery and development, and we look forward to funding the expansion of these efforts and assisting the Company in bringing new, innovative therapies to patients worldwide,” Aman Kumar, Oaktree Co-Portfolio Manager of Life Sciences Lending.